These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 12638402)

  • 1. [Role of organic nitrates in therapy of coronary heart disease in terms of clinical cost-effectiveness].
    Solianik EV; Beliaeva LA; Gel'tser BI
    Klin Med (Mosk); 2002; 80(12):4-9. PubMed ID: 12638402
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost effectiveness of statins in coronary heart disease.
    Franco OH; Peeters A; Looman CW; Bonneux L
    J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Is long-term treatment with nitrates in patients with coronary disease promising?].
    Med Welt; 1982 Jan; 33(2):43-4. PubMed ID: 7057705
    [No Abstract]   [Full Text] [Related]  

  • 4. Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach.
    Martikainen JA; Ottelin AM; Kiviniemi V; Gylling H
    Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):265-72. PubMed ID: 17446806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
    Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
    J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease.
    Hlatky MA; Boothroyd DB; Melsop KA; Brooks MM; Mark DB; Pitt B; Reeder GS; Rogers WJ; Ryan TJ; Whitlow PL; Wiens RD
    Circulation; 2004 Oct; 110(14):1960-6. PubMed ID: 15451795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Coronary heart disease. Nitrate therapy without tolerance].
    Z Kardiol; 1999 Feb; 88(2 Suppl Nitratther):1-4. PubMed ID: 10192152
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care.
    Turner DA; Paul S; Stone MA; Juarez-Garcia A; Squire I; Khunti K
    Heart; 2008 Dec; 94(12):1601-6. PubMed ID: 18450843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How much do the benefits cost? Effects of a home-based training programme on cardiovascular fitness, quality of life, programme cost and adherence for patients with coronary disease.
    Salvetti XM; Oliveira JA; Servantes DM; Vincenzo de Paola AA
    Clin Rehabil; 2008; 22(10-11):987-96. PubMed ID: 18955430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The present status of nitrates in the treatment of ischemic heart disease].
    Stejfa M; Vítovec J
    Vnitr Lek; 1993 Feb; 39(2):172-7. PubMed ID: 8506665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introductory remarks about clinically relevant pharmacokinetic properties of organic nitrates.
    Bogaert M
    Z Kardiol; 1990; 79 Suppl 3():47-9. PubMed ID: 2129143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nitrate therapy for ischemic heart disease and cardiac insufficiency].
    Bertel O; Naegeli B
    Dtsch Med Wochenschr; 1989 Nov; 114(45):1749-53. PubMed ID: 2680418
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe.
    Perkerson KA; Gillespie EL; Coleman CI
    Conn Med; 2005 Jan; 69(1):19-22. PubMed ID: 15736370
    [No Abstract]   [Full Text] [Related]  

  • 16. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK.
    Karnon J; Bakhai A; Brennan A; Pandor A; Flather M; Warren E; Gray D; Akehurst R
    Int J Cardiol; 2006 May; 109(3):307-16. PubMed ID: 16026869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
    Lindgren P; Jönsson B; Yusuf S
    J Intern Med; 2004 May; 255(5):562-70. PubMed ID: 15078498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal hemorrhage.
    Targownik LE; Spiegel BM; Dulai GS; Karsan HA; Gralnek IM
    Am J Gastroenterol; 2004 Jul; 99(7):1306-15. PubMed ID: 15233670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What do we gain from the sixth coronary heart disease drug?
    Warburton RN
    BMJ; 2003 Nov; 327(7426):1237-8. PubMed ID: 14644934
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hemodynamic effects of organic nitrates].
    Kojda G
    Med Monatsschr Pharm; 1998 Jan; 21(1):9-15. PubMed ID: 9499687
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.